机构名称：
¥ 2.0
抗曲妥珠单抗（TRC1和TRC2）或Lapatinib（LRC1和LRC2）的抗性克隆显示出明显的GSDMB上调（图1E）。这些在体外会导致各种细胞模型（乳腺癌和胃癌细胞系，乳腺PDX原发性培养），以及我们在体内发表的观察结果，与PDXS和HER2乳腺癌患者[12]，确认GSDMB促进了对曲妥珠单抗的抵抗力以及Lapatinib。Since TKIs are mainly utilized in trastuzumab pretreated patients [17] (indeed HCC1954 cells are intrinsically resistant to trastuzumab [14, 28]) and there is a need to understand the molecular mechanisms that underlies the TKI derived resistance, we selected lapatinib as the suitable (second line) anti-HER2 therapy to further decipher the connection between GSDMB and drug 反抗。
Gasdermin B过表达调节HER2
主要关键词
相关文件推荐
